Jun 15, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Study Shows Innovative ERT-Based Solution Has The Potential To Address Unmet Clinical
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2710205" data-attributes="member: 124445"><p>Oxyrane, has announced the publication in Nature Biotechnology, results of its landmark study in novel enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs). Oxyrane, in collaboration with VIB researchers from Ghent University and Vrije Universiteit Brussels, have developed a new technology that enables a more efficient approach to ERT production for LSD treatments, as well as the potential to significantly improve future treatments for debilitating and often life-threatening LSDs such as Pompe disease, Fabry disease and Hunter's syndrome...<img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/JZ7ssRLD3L8" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/JZ7ssRLD3L8/252973.php" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2710205, member: 124445"] Oxyrane, has announced the publication in Nature Biotechnology, results of its landmark study in novel enzyme replacement therapy (ERT) for lysosomal storage diseases (LSDs). Oxyrane, in collaboration with VIB researchers from Ghent University and Vrije Universiteit Brussels, have developed a new technology that enables a more efficient approach to ERT production for LSD treatments, as well as the potential to significantly improve future treatments for debilitating and often life-threatening LSDs such as Pompe disease, Fabry disease and Hunter's syndrome...[IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/JZ7ssRLD3L8[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/JZ7ssRLD3L8/252973.php]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top